StockData
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE) stock

GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3014% below fair value
$4.34−0.22 (-4.82%)

Close on Nov 18, 2026Market cap $483.95MP/E –Yield –

Gyre Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Gyre Therapeutics's enterprise value was $428.92M on Nov 11, 2026, against $679.85M a year earlier. Over the last 5 years it ranged from $109.17M to $1.39B, with a median of $650.41M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$428.92M-30.5%
2025Dec 31, 2025$617.13M-41.1%
2024Dec 31, 2024$1.05B+7.7%
2023Dec 29, 2023$973.43M+328.3%
2022Dec 30, 2022$227.26M-4.2%
2021Dec 31, 2021$237.14M-88.1%
2020Dec 31, 2020$1.99B+73.6%
2019Dec 31, 2019$1.14B-10.9%
2018Dec 31, 2018$1.28B+50.3%
2017Dec 29, 2017$854.45M+782.2%
2016Dec 30, 2016$96.86M-80.6%
2015Dec 31, 2015$499.02M+982.4%
2014Dec 31, 2014$46.10M-28.0%
2013Dec 31, 2013$64.01M+141.7%
2012Dec 31, 2012$26.49M+961.4%
2011Dec 30, 2011$2.50M-99.6%
2010Dec 31, 2010$691.45M–

More Gyre Therapeutics figures

See a number that looks wrong?